Novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia of chronic disease associated with cancer.
Anaemia is a common haematologic disorder in patients with cancer and has a multifactorial aetiology, including the effects of the malignancy itself and residual effects from previous therapy. Novel erythropoiesis stimulating protein (NESP, darbepoetin alfa), a protein with additional sialic acid compared with erythropoietin (EPO), stimulates erythropoiesis by the same mechanism as recombinant human erythropoietin (rHuEPO) but it is biochemically distinct. NESP, with its approximately 3-fold greater serum half-life, can maintain haemoglobin levels as effectively as rHuEPO in anaemic patients with chronic renal failure and do so with less frequent dosing. We investigated the ability of NESP to safely increase haemoglobin levels of anaemic patients with non-myeloid malignancies not receiving chemotherapy. NESP was administered under the supervision of a physician at doses of 0.5, 1.0, 2.25 or 4.5 mcg kg(-1)wk(-1)for a maximum of 12 weeks. This report includes 89 patients completing the study by November 2000. NESP was well tolerated, with no reported dose-limiting toxicities or treatment-related severe adverse events. Increasing doses of NESP corresponded with increased efficacy. The percentage (95% confidence interval) of patients responding ranged from 61% (42%, 77%) in the 1.0 mcg kg(-1)wk(-1)group to 83% (65%, 94%) in the 4.5 mcg kg(-1)wk(-1)group.
Smith
R E
RE
South Carolina Oncology Associates, Suite IA, 1301 Taylor, Columbia, SC 29201, USA.
Jaiyesimi
I A
IA
Meza
L A
LA
Tchekmedyian
N S
NS
Chan
D
D
Griffith
H
H
Brosman
S
S
Bukowski
R
R
Murdoch
M
M
Rarick
M
M
Saven
A
A
Colowick
A B
AB
Fleishman
A
A
Gayko
U
U
Glaspy
J
J
D000328:Adult; D000368:Aged; D000740:Anemia / Q000188:drug therapy* / Q000209:etiology / Q000628:therapy; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D000068256:Darbepoetin alfa; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D017707:Erythrocyte Transfusion / Q000706:statistics & numerical data; D004920:Erythropoiesis / Q000187:drug effects; D004921:Erythropoietin / Q000008:administration & dosage* / Q000009:adverse effects / Q000031:analogs & derivatives / Q000737:chemistry / Q000276:immunology / Q000627:therapeutic use; D005221:Fatigue / Q000209:etiology / Q000517:prevention & control; D005260:Female; D006207:Half-Life; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D007279:Injections, Subcutaneous; D015993:Life Tables; D008297:Male; D008875:Middle Aged; D019158:N-Acetylneuraminic Acid / Q000737:chemistry; D009369:Neoplasms / Q000097:blood / Q000150:complications* / Q000188:drug therapy; D011788:Quality of Life; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000009:adverse effects / Q000737:chemistry / Q000276:immunology / Q000627:therapeutic use; D012449:Safety; D016896:Treatment Outcome
D006454:Hemoglobins; D011994:Recombinant Proteins; D004921:Erythropoietin; D000068256:Darbepoetin alfa; D019158:N-Acetylneuraminic Acid